Phase II Study of the Anti-Ganglioside GD3 Mouse/Human Chimeric Antibody KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Ecromeximab (Primary) ; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2018 Status changed from active, no longer recruiting to completed.
- 20 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 11 May 2015 Planned End Date changed from 1 Oct 2013 to 1 Jul 2015, according to to ClinicalTrials.gov record.